Background/Objectives: The BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There is a need for real-world data in low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression-free survival (PFS) and in the first- and second-line setting and sequences of treatment regimens. Methods: We retrospectively analyze patients from ten oncology centers in Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 and July 2023. Results: A total of 161 patients with metastatic CRC and BRAFV600E-mutation. The median age was 58.5 (IQR 47–69), and 21.7% were MMR-deficient (dMMR). Of these patients, 93.8% received first-line treatment. With a median follow-up of 23 months (95% CI 16.5–33.4 months), the median PFS was 9 months (95% CI 7.4–10.5 months). The most common regimen in first line setting was doublet chemotherapy plus anti-VEGF for 49% of the patients. Twenty-six percent of the patients received BRAF inhibitors in the second-line setting, with a median PFS of 5.2 months (95% CI 4.9—NR); the overall response rate (ORR) was 10.5%. Conclusions: This study represents, to the best of our knowledge, the largest published real-world cohort of BRAFV600E-mutated CRC in Latin America. The heterogeneity of the treatments reflects the existence of barriers to access to high-cost drugs in our country. Cooperative efforts are needed to understand the particular characteristics of this subgroup of patients.
Background/Objectives: BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There is a need for real-world data in low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression free survival (PFS) and overall survival (OS) in the first-line setting, and sequences of treatment regimens. Methods: We retrospective analyze patients from ten oncology centers in Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 and July 2023. Results: A total of 161 patients with metastatic CRC and BRAFV600E-mutation. The median age was 58.5 (IQR 47-69) and 21.7% were MMR-deficient (dMMR). 93.8% of the patients received first-line treatment. With a median follow-up of 23 months (95% CI 16.5 - 33.4 months), the median OS was 20.6 months (95% CI 18.4 - 29 months) and PFS 9 months (95% CI 7.4 - 10.5 months). The most common regimen was doublet chemotherapy plus anti-VEGF in 49%. 26% received BRAF inhibitors in second line setting. Conclusions: This study represents, to the best of our knowledge, the largest published real-world cohort of BRAFV600E-mutated CRC in Latin America. The heterogeneity in treatments reflect the existence of barriers to access high-cost drugs in our country. Cooperative efforts are needed to understand the particular characteristics of this subgroup of patients.
Los tumores neuroendocrinos (TNEs) representan un grupo heterogéneo de neoplasias, caracterizadas por una amplia variabilidad en su comportamiento clínico, biológico y molecular. Esta diversidad, tanto a nivel de presentación como de respuesta a los tratamientos, representa un desafío significativo en la práctica clínica oncológica. Los TNEs pueden originarse en diversos órganos del cuerpo, lo que agrega complejidad a su diagnóstico y manejo. La identificación temprana, junto con una clasificación precisa, es fundamental para establecer un enfoque terapéutico adecuado. En esta guía, un equipo de destacados profesionales argentinos, especializados en el estudio y tratamiento de los TNEs, se ha reunido para ofrecer una actualización integral sobre las estrategias más recientes en el diagnóstico, manejo y tratamiento de estos tumores. Este documento tiene como objetivo proporcionar una herramienta útil para oncólogos y otros profesionales de la salud, facilitando una comprensión más clara sobre las opciones terapéuticas disponibles, las indicaciones basadas en evidencia y los avances en la investigación que están configurando el tratamiento de los TNEs en Argentina y el mundo.